Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983 · cited 1×
“However, it might not be necessary for a small molecule to cover the entire protein-binding surface, because the subset of the interface that contributes to high-affinity binding (the 'hot spot') is often much smaller ( Box 1”
BackgroundSelf-citationThe atomic structure of protein-protein recognition sites 1 1Edited by A. R. Fersht
Conte, L. L., Chothia, C., & Janin, J. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2439 · Cited by 1,964 · cited 1×
“Approximately 750–1,500 A 2 of surface area is buried on each side of the interfac”
BackgroundEffects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase
Huang, Z., Huang, P. L., Panahian, N., Dalkara, T., Fishman, M. C., & Moskowitz, M. A. (1994) · Science · doi:10.1126/science.7522345 · Cited by 1,565 · cited 1×
“, and in neurons, where both positive and negative effects have been observe”
BackgroundHarding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476
Wang, J.-L., Liu, D., Zhang, Z.-J., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., & Huang, Z. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7124 · Cited by 1,201
Mayer, M., & Meyer, B. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0100120 · Cited by 1,200
BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death
Huang, D. C. S., & Strasser, A. (2000) · Cell · doi:10.1016/s0092-8674(00)00187-2 · Cited by 1,043
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042 · cited 1×
“Shoichet and co-workers have described a surprisingly common inhibitory mechanism that arises when hydrophobic or amphipathic small molecules form large aggregates, micelles or liposome”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Inducible nitric oxide synthase: what difference does it make?
Nathan, C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119782 · Cited by 943 · cited 1×
“cgi?l=4843">iNOS ), on the other hand, is implicated in tissue damage during inflammatio”
BackgroundCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
Modern analytical ultracentrifugation in protein science: A tutorial review
Lebowitz, J., Lewis, M. S., & Schuck, P. (2002) · Protein Science · doi:10.1110/ps.0207702 · Cited by 777
Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Jordan, M. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354290 · Cited by 775
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Unraveling hot spots in binding interfaces: progress and challenges
DeLano, W. L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00283-x · Cited by 767 · cited 1×
“However, it might not be necessary for a small molecule to cover the entire protein-binding surface, because the subset of the interface that contributes to high-affinity binding (the 'hot spot') is often much smaller ( Box 1”
BackgroundNitric Oxide as a Signaling Molecule in the Vascular System: An Overview
Ignarro, L. J., Cirino, G., Casini, A., & Napoli, C. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199912000-00016 · Cited by 763
Cysteine Proteases and Their Inhibitors
Otto, H.-H., & Schirmeister, T. (1997) · Chemical Reviews · doi:10.1021/cr950025u · Cited by 759 · cited 1×
“Ro 028-2750 contains an aldehyde, which can covalently modify protein”
BackgroundImplications of protein flexibility for drug discovery
Teague, S. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1129 · Cited by 755 · cited 1×
“Therefore there might be binding-site conformations that are well-suited to small-molecule binding yet are not visible in a single crystal structur”
BackgroundDirect measurement of protein binding energetics by isothermal titration calorimetry
Leavitt, S., & Freire, E. (2001) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00248-7 · Cited by 691
The Interaction Properties of Costimulatory Molecules Revisited
Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 684
Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin
Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., & Dower, W. J. (1996) · Science · doi:10.1126/science.273.5274.458 · Cited by 672
Convergent Solutions to Binding at a Protein-Protein Interface
DeLano, W. L., Ultsch, M. H., de, A. M., Vos, & Wells, J. A. (2000) · Science · doi:10.1126/science.287.5456.1279 · Cited by 672 · cited 1×
“In addition, for many protein–protein interactions, the apparent complementarity between the two surfaces involves a significant degree of protein flexibility and adaptivit”
BackgroundSelf-citationA Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598 · cited 1×
“Shoichet and co-workers have described a surprisingly common inhibitory mechanism that arises when hydrophobic or amphipathic small molecules form large aggregates, micelles or liposome”
BackgroundMa, B., Elkayam, T., Wolfson, H., & Nussinov, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1030237100 · Cited by 595
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., & Yuan, J. (2001) · Nature Cell Biology · doi:10.1038/35055085 · Cited by 550
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Shimaoka, M., Xiao, T., Liu, J.-H., Yang, Y., Dong, Y., Jun, C.-D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., et al. (2003) · Cell · doi:10.1016/s0092-8674(02)01257-6 · Cited by 516
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Molecular Interactions Mediating T Cell Antigen Recognition
Merwe, P. A. V. D., & Davis, S. J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141036 · Cited by 501
Integrin avidity regulation: are changes in affinity and conformation underemphasized?
Carman, C. V., & Springer, T. A. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.08.003 · Cited by 500 · cited 1×
“) Binding of ICAM1 to LFA1 seems to be regulated by conformational changes in LFA1 and by clustering of LFA1 on the surface of activated cell”
BackgroundProtein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis
Stites, W. E. (1997) · Chemical Reviews · doi:10.1021/cr960387h · Cited by 491
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 489 · cited 1×
“The crystal structure of B7-1 bound to CTLA4 emphasizes the possible multivalency of this protein–protein interactio”
BackgroundIdentification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs
Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030191r · Cited by 476 · cited 1×
“Shoichet and co-workers have described a surprisingly common inhibitory mechanism that arises when hydrophobic or amphipathic small molecules form large aggregates, micelles or liposome”
BackgroundBiology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475 · cited 1×
“cgi?Q=3559%20or%203560%20or%203561%20not%206678&ORG=Hs">IL-2R ), which contains α, β and γ chains, causes proliferation and differentiation of activated cell”
BackgroundRegulation of apoptosis by Bcl‐2 family proteins
Burlacu, A. (2003) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2003.tb00225.x · Cited by 468
Site-directed ligand discovery
Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466
Self-citationAntimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
Tzung, S.-P., Kim, K. M., Basañez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y. J., & Hockenbery, D. M. (2001) · Nature Cell Biology · doi:10.1038/35055095 · Cited by 452
Multiple diverse ligands binding at a single protein site: A matter of pre‐existing populations
Ma, B., Shatsky, M., Wolfson, H. J., & Nussinov, R. (2002) · Protein Science · doi:10.1110/ps.21302 · Cited by 420
Wiesmann, C., Ultsch, M. H., Bass, S. H., & de Vos, A. M. (1999) · Nature · doi:10.1038/43705 · Cited by 415
Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10001 · Cited by 408 · cited 1×
“By binding to other cell-surface molecules called cell-adhesion molecules (CAMs), integrins mediate cell–cell adhesion, extravasation and T-cell activatio”
BackgroundPeptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine
Cwirla, S. E., Balasubramanian, P., Duffin, D. J., Wagstrom, C. R., Gates, C. M., Singer, S. C., Davis, A. M., Tansik, R. L., Mattheakis, L. C., Boytos, C. M., et al. (1997) · Science · doi:10.1126/science.276.5319.1696 · Cited by 403
Humphries, M. J. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280311 · Cited by 398
Binding of small molecules to an adaptive protein–protein interface
Arkin, M. R., Randal, M., DeLano, W. L., Hyde, J., Luong, T. N., Oslob, J. D., Raphael, D. R., Taylor, L., Wang, J., McDowell, R. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252756299 · Cited by 375
Self-citationBoehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000017s · Cited by 375
Hajduk, P. J., Olejniczak, E. T., & Fesik, S. W. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9715962 · Cited by 371
Liu, G., Huth, J. R., Olejniczak, E. T., Mendoza, R. R., DeVries, P. J., Leitza, S. T., Reilly, E. B., Okasinski, G. F., Fesik, S. W., & von Geldern, T. W. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000503f · Cited by 359
Therapeutic antagonists and conformational regulation of integrin function
Shimaoka, M., & Springer, T. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1174 · Cited by 349 · cited 1×
“; the extracellular protein LFA1 is elaborately regulated by metal ions outside the cell and by signalling pathways inside the cel”
BackgroundBlocking NO synthesis: how, where and why?
Vallance, P., & Leiper, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd960 · Cited by 331 · cited 1×
“, prompting researchers to look for inhibitors that are selective for iNO”
BackgroundIbáñez, C. F., Ebendal, T., Barbany, G., Murray-Rust, J., Blundell, T. L., & Persson, H. (1992) · Cell · doi:10.1016/0092-8674(92)90413-7 · Cited by 327
T-cell integrins: more than just sticking points
Hogg, N., Laschinger, M., Giles, K., & McDowall, A. (2003) · Journal of Cell Science · doi:10.1242/jcs.00876 · Cited by 322 · cited 1×
“) Binding of ICAM1 to LFA1 seems to be regulated by conformational changes in LFA1 and by clustering of LFA1 on the surface of activated cell”
BackgroundDiscovering novel ligands for macromolecules using X-ray crystallographic screening
Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., & Greer, J. (2000) · Nature Biotechnology · doi:10.1038/80319 · Cited by 322
Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening
Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010016f · Cited by 315
Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin.
Qu, A., & Leahy, D. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10277 · Cited by 304
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292 · cited 1×
“For these reasons, protein–protein interactions have been of great interest to drug discovery; however, developing small-molecule antagonists has been difficult (for recent reviews see Ref”
BackgroundConservation of polar residues as hot spots at protein interfaces
Hu, Z., Ma, B., Wolfson, H., & Nussinov, R. (2000) · Proteins: Structure, Function, and Genetics · doi:10.1002/(sici)1097-0134(20000601)39:4<331::aid-prot60>3.0.co;2-a · Cited by 290
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281 · cited 1×
“Each of these approaches, including HTS, has been used to identify initial small-molecule antagonists of protein–protein interactions, and these methods have been recently reviewed and evaluate”
MethodChalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery
Fejzo, J., Lepre, C. A., Peng, J. W., Bemis, G. W., Ajay, Murcko, M. A., & Moore, J. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80022-8 · Cited by 271
Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly
Braisted, A. C., Oslob, J. D., Delano, W. L., Hyde, J., McDowell, R. S., Waal, N., Yu, C., Arkin, M. R., & Raimundo, B. C. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034247i · Cited by 256
Self-citationKallen, J., Welzenbach, K., Ramage, P., Geyl, D., Kriwacki, R., Legge, G., Cottens, S., Weitz-Schmidt, G., & Hommel, U. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3047 · Cited by 256
Development of a Potent Bcl-xLAntagonist Based on α-Helix Mimicry
Kutzki, O., Park, H. S., Ernst, J. T., Orner, B. P., Yin, H., & Hamilton, A. D. (2002) · Journal of the American Chemical Society · doi:10.1021/ja026861k · Cited by 253
Structure and Dimerization of a Soluble Form of B7-1
Ikemizu, S., Gilbert, R. J. C., Fennelly, J. A., Collins, A. V., Harlos, K., Jones, E. Y., Stuart, D. I., & Davis, S. J. (2000) · Immunity · doi:10.1016/s1074-7613(00)80158-2 · Cited by 249 · cited 1×
“The crystal structure of B7-1 bound to CTLA4 emphasizes the possible multivalency of this protein–protein interactio”
BackgroundNMR-based screening in drug discovery
Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1999) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500003528 · Cited by 229
Liu, G., Link, J. T., Pei, Z., Reilly, E. B., Leitza, S. T., Nguyen, B., Marsh, K. C., Okasinski, G. F., von Geldern, T. W., Ormes, M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002782 · Cited by 220
In situ assembly of enzyme inhibitors using extended tethering
Erlanson, D. A., Lam, J. W., Wiesmann, C., Luong, T. N., Simmons, R. L., DeLano, W. L., Choong, I. C., Burdett, M. T., Flanagan, W. M., Lee, D., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt786 · Cited by 203
McMillan, K., Adler, M., Auld, D. S., Baldwin, J. J., Blasko, E., Browne, L. J., Chelsky, D., Davey, D., Dolle, R. E., Eagen, K. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1506 · Cited by 201 · cited 1×
“8 ) that allosterically inhibit the function of iNOS by binding to the haem cofactor in the protein active site and disrupting protein dimerizatio”
BackgroundNerve growth factor: structure and function
Wiesmann, C., & de Vos, A. M. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000898 · Cited by 199
Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins
Goodman, S. L., Hölzemann, G., Sulyok, G. A. G., & Kessler, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0102598 · Cited by 196
Lu, C., Shimaoka, M., Zang, Q., Takagi, J., & Springer, T. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041618598 · Cited by 192
Structural stability of binding sites: Consequences for binding affinity and allosteric effects
Luque, I., & Freire, E. (2000) · Proteins: Structure, Function, and Genetics · doi:10.1002/1097-0134(2000)41:4+<63::aid-prot60>3.0.co;2-6 · Cited by 191
Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site
Fairbrother, W. J., Christinger, H. W., Cochran, A. G., Fuh, G., Keenan, C. J., Quan, C., Shriver, S. K., Tom, J. Y. K., Wells, J. A., & Cunningham, B. C. (1998) · Biochemistry · doi:10.1021/bi981931e · Cited by 190
Self-citationExploring Protein–Protein Interactions with Phage Display
Sidhu, S. S., Fairbrother, W. J., & Deshayes, K. (2003) · ChemBioChem · doi:10.1002/cbic.200390008 · Cited by 190
High-Throughput Nuclear Magnetic Resonance-Based Screening
Hajduk, P. J., Gerfin, T., Boehlen, J.-M., Häberli, M., Marek, D., & Fesik, S. W. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9901475 · Cited by 184
Structural Plasticity in a Remodeled Protein-Protein Interface
Atwell, S., Ultsch, M., De Vos, A. M., & Wells, J. A. (1997) · Science · doi:10.1126/science.278.5340.1125 · Cited by 180
Self-citationIsolation and Structure Elucidation of Chlorofusin, a Novel p53-MDM2 Antagonist from a Fusarium sp.
Duncan, S. J., Grüschow, S., Williams, D. H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S. K., & Moore, M. (2001) · Journal of the American Chemical Society · doi:10.1021/ja002940p · Cited by 172
Gadek, T. R., Burdick, D. J., McDowell, R. S., Stanley, M. S., Marsters, J. C., Paris, K. J., Oare, D. A., Reynolds, M. E., Ladner, C., Zioncheck, K. A., et al. (2002) · Science · doi:10.1126/science.295.5557.1086 · Cited by 172 · cited 1×
“The other class of allosteric inhibitors seems to bind at the junction between the I-domain and the I-like domain, blocking the interaction of the α7 helix with the I-like domai”
BackgroundHuth, J. R., Olejniczak, E. T., Mendoza, R., Liang, H., Harris, E. A. S., Lupher, M. L., Wilson, A. E., Fesik, S. W., & Staunton, D. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5231 · Cited by 161
Neurotrophin receptors: mediators of life and death
Chao, M., Casaccia-Bonnefil, P., Carter, B., Chittka, A., Kong, H., & Yoon, S. O. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00036-2 · Cited by 159
Gyurko, R., Leupen, S., & Huang, P. L. (2002) · Endocrinology · doi:10.1210/endo.143.7.8921 · Cited by 157 · cited 1×
“, and in neurons, where both positive and negative effects have been observe”
BackgroundInducible Nitric Oxide Synthase - Time for Reappraisal
Lirk, P., Hoffmann, G., & Rieder, J. (2002) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010023344913 · Cited by 149 · cited 1×
“, prompting researchers to look for inhibitors that are selective for iNO”
BackgroundProtein–protein interfaces: mimics and inhibitors
Cochran, A. G. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(01)00262-9 · Cited by 149 · cited 1×
“Clinical data have demonstrated the importance of IL-2 and IL-2Rα in mediating immune disorders; two anti-IL-2Rα antibodies have been approved for use in transplant rejectio”
BackgroundThe use of antibodies against the IL-2 receptor in transplantation
Waldmann, T. A., & O’Shea, J. J. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80215-x · Cited by 147 · cited 1×
“Clinical data have demonstrated the importance of IL-2 and IL-2Rα in mediating immune disorders; two anti-IL-2Rα antibodies have been approved for use in transplant rejectio”
BackgroundRANDI, A. M., & Hogg, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99884-4 · Cited by 143
BACTERIOPHAGE DISPLAY AND DISCOVERY OF PEPTIDE LEADS FOR DRUG DEVELOPMENT
Lowman, H. B. (1997) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.26.1.401 · Cited by 143
Carter, P. H., Scherle, P. A., Muckelbauer, J. A., Voss, M. E., Liu, R.-Q., Thompson, L. A., Tebben, A. J., Solomon, K. A., Lo, Y. C., Li, Z., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211178398 · Cited by 141
Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion
Kelly, T. A., Jeanfavre, D. D., McNeil, D. W., Woska, J. R., Reilly, P. L., Mainolfi, E. A., Kishimoto, K. M., Nabozny, G. H., X.-J.Zinter, R. W., Bormann, B., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5173 · Cited by 139
Humphries, M. J. (2000) · Biochemical Society Transactions · doi:10.1042/bst028a049a · Cited by 136
The Two-Dimensional Transferred Nuclear Overhauser Effect: Theory and Practice
Campbell, A. P., & Sykes, B. D. (1993) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.22.060193.000531 · Cited by 134
Shimaoka, M., Salas, A., Yang, W. Y., Weitz‐Schmidt, G., & Springer, T. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00238-3 · Cited by 134 · cited 1×
“The other class of allosteric inhibitors seems to bind at the junction between the I-domain and the I-like domain, blocking the interaction of the α7 helix with the I-like domai”
BackgroundLast-Barney, K., Davidson, W. C., Cardozo, M. G., Frye, L. L., Grygon, C. A., Hopkins, J. L., Jeanfavre, D. D., Pav, S., Qian, C., Stevenson, J. M., et al. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0104249 · Cited by 132
The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin
Qu, A., & Leahy, D. J. (1996) · Structure · doi:10.1016/s0969-2126(96)00100-1 · Cited by 130 · cited 1×
“This hypothesis is consistent with the rigid-body motion of the α7 helix observed by NMR and crystallograph”
MethodEnkhbaatar, P., Murakami, K., Shimoda, K., Mizutani, A., Traber, L. D., Phillips, G. B., Parkinson, J. F., Cox, R. A., Hawkins, H. K., Herndon, D. N., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1031pp · Cited by 130 · cited 1×
“Both BBS-2 and PPA250 were shown to be active in animal models of diseas”
BackgroundTilley, J. W., Chen, L., Fry, D. C., Emerson, S. D., Powers, G. D., Biondi, D., Varnell, T., Trilles, R., Guthrie, R., Mennona, F., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja970702x · Cited by 129
Antithrombotic agents: From RGD to peptide mimetics
Ojima, I., Chakravarty, S., & Dong, Q. (1995) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(95)00036-g · Cited by 127
Jackson, D. Y. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394737 · Cited by 121
Scarborough, R. M., & Gretler, D. D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000022w · Cited by 121
Small molecule antagonists of proteins
Gadek, T. R., & Nicholas, J. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01479-x · Cited by 120
Lugovskoy, A. A., Degterev, A. I., Fahmy, A. F., Zhou, P., Gross, J. D., Yuan, J., & Wagner, G. (2002) · Journal of the American Chemical Society · doi:10.1021/ja011239y · Cited by 116
Tsai, C.-J., Lin, S. L., Wolfson, H. J., & Nussinov, R. (1996) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239609106582 · Cited by 116
Structure-based screening of low-affinity compounds
Carr, R. A. E., & Jhoti, H. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02245-6 · Cited by 112
Darlington, P. J., Baroja, M. L., Chau, T. A., Siu, E., Ling, V., Carreno, B. M., & Madrenas, J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011868 · Cited by 109
The Chemical Biology of Apoptosis
Huang, Z. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00247-8 · Cited by 109
Potent Small-Molecule Binding to a Dynamic Hot Spot on IL-2
Thanos, C. D., Randal, M., & Wells, J. A. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0382617 · Cited by 105 · cited 1×
“; several X-ray crystal structures of IL-2 further support this notion, because the structures vary significantly in the hydrophobic portion of the binding site and the adjacent loop”
BackgroundSelf-citationScott, J. K., Huang, S., Gangadhar, B. P., Samoriski, G. M., Clapp, P., Gross, R. A., Taussig, R., & Smrcka, A. V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.767 · Cited by 104
Sauvé, K., Nachman, M., Spence, C., Bailon, P., Campbell, E., Tsien, W. H., Kondas, J. A., Hakimi, J., & Ju, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4636 · Cited by 100
Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library: New Selective αvβ3 Integrin Antagonists
Sulyok, G. A. G., Gibson, C., Goodman, S. L., Hölzemann, G., Wiesner, M., & Kessler, H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004953 · Cited by 100
Blasko, E., Glaser, C. B., Devlin, J. J., Xia, W., Feldman, R. I., Polokoff, M. A., Phillips, G. B., Whitlow, M., Auld, D. S., McMillan, K., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105691200 · Cited by 94 · cited 1×
“8 ) that allosterically inhibit the function of iNOS by binding to the haem cofactor in the protein active site and disrupting protein dimerizatio”
BackgroundSurvey of the year 2000 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2001) · Journal of Molecular Recognition · doi:10.1002/jmr.547 · Cited by 94
Characterizing a Drug’s Primary Binding Site on Albumin
Day, Y. S. N., & Myszka, D. G. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10293 · Cited by 89
Pillutla, R. C., Hsiao, K.-C., Beasley, J. R., Brandt, J., Østergaard, S., Hansen, P. H., Spetzler, J. C., Danielsen, G. M., Andersen, A. S., Brissette, R. E., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202119200 · Cited by 89
Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., & Liu, Z. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00084-8 · Cited by 88
Second-Site NMR Screening with a Spin-Labeled First Ligand
Jahnke, W., Perez, L. B., PARIS, C. G., Strauss, A., Fendrich, G., & Nalin, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001241+ · Cited by 85
Response : Unraveling the Structure of IL-2
McKay, D. (1992) · Science · doi:10.1126/science.257.5068.412 · Cited by 84
Antibodies as therapeutic agents: vive la renaissance!
Stockwin, L., & Holmes, S. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.7.1133 · Cited by 82 · cited 1×
“The current excitement surrounding therapeutic antibodies vividly demonstrates the value of such target”
BackgroundZurawski, S., Vega, F., Doyle, E. L., Huyghe, B. G., Flaherty, K. M., McKay, D., & Zurawski, G. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06206.x · Cited by 82
Welzenbach, K., Hommel, U., & Weitz-Schmidt, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110521200 · Cited by 81 · cited 1×
“The other class of allosteric inhibitors seems to bind at the junction between the I-domain and the I-like domain, blocking the interaction of the α7 helix with the I-like domai”
BackgroundLuxury accommodations: the expanding role of structural plasticity in protein–protein interactions
Sundberg, E. J., & Mariuzza, R. A. (2000) · Structure · doi:10.1016/s0969-2126(00)00167-2 · Cited by 80 · cited 1×
“In addition, for many protein–protein interactions, the apparent complementarity between the two surfaces involves a significant degree of protein flexibility and adaptivit”
BackgroundKim, K. M., Giedt, C. D., Basáñez, G., O’Neill, J., Hill, J. J., Han, Y.-H., Tzung, S.-P., Zimmerberg, J. J., Hockenbery, D. M., & Zhang, K. Y. J. (2001) · Biochemistry · doi:10.1021/bi002368e · Cited by 78 · cited 1×
“It is noteworthy that this site seems to bind amino naphthalene sulphonic acid (ANS), a hydrophobic dye used to detect exposed hydrophobic areas and partially denatured protein”
BackgroundNGF ligand alters NGF signaling via p75NTR and TrkA
Niederhauser, O., Mangold, M., Schubenel, R., Kusznir, E. A., Schmidt, D., & Hertel, C. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000801)61:3<263::aid-jnr4>3.0.co;2-m · Cited by 77
NMR solution structure of the inserted domain of human leukocyte function associated antigen-1
Legge, G. B., Kriwacki, R. W., Chung, J., Hommel, U., Ramage, P., Case, D. A., Dyson, H. J., & Wright, P. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3409 · Cited by 76 · cited 1×
“The isolated I-domain of LFA1 has been recombinantly expressed and characterized by NM”
MethodBorthwick, A. D., Crame, A. J., Ertl, P. F., Exall, A. M., Haley, T. M., Hart, G. J., Mason, A. M., Pennell, A. M. K., Singh, O. M. P., Weingarten, G. G., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102203 · Cited by 71
Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications
Mousa, S. A. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00350-2 · Cited by 67
A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation
Berard, J. L., Velez, R. L., Freeman, R. B., & Tsunoda, S. M. (1999) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.15.1127.30582 · Cited by 67 · cited 1×
“Clinical data have demonstrated the importance of IL-2 and IL-2Rα in mediating immune disorders; two anti-IL-2Rα antibodies have been approved for use in transplant rejectio”
BackgroundSecond-Site NMR Screening and Linker Design
Jahnke, W., Flörsheimer, A., Blommers, M. J. J., PARIS, C. G., Heim, J., Nalin, C. M., & Perez, L. B. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033392778 · Cited by 66
Lupher, M., Harris, E. A. S., Beals, C. R., Sui, L., Liddington, R., & Staunton, D. E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1431 · Cited by 65
Design of Adenosine Kinase Inhibitors from the NMR-Based Screening of Fragments
Hajduk, P. J., Gomtsyan, A. R., DiDomenico, S., Cowart, M., Bayburt, E. K., Solomon, L. R., Severin, J. M., Smith, R. A., Walter, K. A., Holzman, T. F., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000373a · Cited by 64
Winn, M., Reilly, E. B., Liu, G., Huth, J. R., Jae, H.-S., Freeman, J. C., Pei, Z., Xin, Z., Lynch, J., Kester, J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0103108 · Cited by 58
Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1
Erbe, D. V., Wang, S., Xing, Y., & Tobin, J. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110162200 · Cited by 57
A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function
Woska, J. R., Shih, D.-T., Taqueti, V. R., Hogg, N., Kelly, T. A., & Kishimoto, T. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.2.329 · Cited by 56
Covalent modification as a strategy to block protein–protein interactions with small-molecule drugs
Way, J. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00049-6 · Cited by 55
General Solid-Phase Method for the Preparation of Mechanism-Based Cysteine Protease Inhibitors
Lee, A., Huang, L., & Ellman, J. A. (1999) · Journal of the American Chemical Society · doi:10.1021/ja992009a · Cited by 52 · cited 1×
“Ro 028-2750 contains an aldehyde, which can covalently modify protein”
BackgroundGreen, N. J., Xiang, J. S., Chen, J., Chen, L.-R., Davies, A. M., Erbe, D., Tam, S., & Tobin, J. F. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00183-4 · Cited by 51
Emerson, S. D., Palermo, R. E., Liu, C., Tilley, J., Chen, L., Danho, W., Madison, V., Greeley, D. N., Ju, G., & Fry, D. C. (2003) · Protein Science · doi:10.1110/ps.0232803 · Cited by 51
Enkhbaatar, P., Murakami, K., Shimoda, K., Mizutani, A., Traber, L. D., Phillips, G. B., Parkinson, J. F., Salsbury, J. R., Biondo, N., Schmalstieg, F. C., et al. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00055.2003 · Cited by 50
1,4-Diazepane-2-ones as novel inhibitors of LFA-1
Wattanasin, S., Albert, R., Ehrhardt, C., Roche, D., Sabio, M. L., Hommel, U., Welzenbach, K., & Weitz‐Schmidt, G. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00991-5 · Cited by 50
Discovery and Characterization of Cooperative Ligand Binding in the Adaptive Region of Interleukin-2
Hyde, J., Braisted, A. C., Randal, M., & Arkin, M. R. (2003) · Biochemistry · doi:10.1021/bi034138g · Cited by 49
Self-citationStable “zeta” peptides that act as potent antagonists of the high-affinity IgE receptor
Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A., & Lowman, H. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022635599 · Cited by 49
The Solution Structure of the F42A Mutant of Human Interleukin 2
Mott, H. R., BAINES, B. S., Hall, R. M., Cooke, R. M., Driscoll, P. C., Weir, M. P., & Campbell, I. D. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.0194 · Cited by 48
Woska, J. R., Morelock, M. M., Jeanfavre, D. D., & Bormann, B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.12.4680 · Cited by 48
Three-dimensional Structural Interactions of Insulin and Its Receptor
Yip, C. C., & Ottensmeyer, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r300021200 · Cited by 48 · cited 1×
“The insulin receptor, for example, is activated by a conformational change induced by the binding of insuli”
BackgroundDiscovery of a New Phosphotyrosine Mimetic for PTP1B Using Breakaway Tethering
Erlanson, D. A., McDowell, R. S., He, M. M., Randal, M., Simmons, R. L., Kung, J., Waight, A., & Hansen, S. K. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034440c · Cited by 47
Thibault, G. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.5.1137 · Cited by 45
Applications of SHAPES Screening in Drug Discovery
Lepre, C. A., Peng, J. W., Fejzo, J., Abdul-Manan, N., Pocas, J. R., Jacobs, M. D., Xie, X., & Moore, J. M. (2002) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207023329950 · Cited by 43
Ohtsuka, M., Konno, F., Honda, H., Oikawa, T., Ishikawa, M., Iwase, N., Isomae, K., Ishii, F., Hemmi, H., & Sato, S. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035857 · Cited by 43 · cited 1×
“8 ) that allosterically inhibit the function of iNOS by binding to the haem cofactor in the protein active site and disrupting protein dimerizatio”
BackgroundProtein-Protein Interactions: Lessons Learned
Sharma, S., Ramsey, T. M., & Bair, K. W. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354191 · Cited by 38 · cited 1×
“Each of these approaches, including HTS, has been used to identify initial small-molecule antagonists of protein–protein interactions, and these methods have been recently reviewed and evaluate”
MethodSchaffer, M. L., Deshayes, K., Nakamura, G. R., Sidhu, S. S., & Skelton, N. J. (2003) · Biochemistry · doi:10.1021/bi034386c · Cited by 37
Philo, J. S. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)21189-0 · Cited by 36
Combinatorial Chemistry Techniques Applied to Nonpeptide lntegrin Antagonists
Hoekstra, W. J., & Poulter, B. L. (1998) · Current Medicinal Chemistry · doi:10.2174/0929867305666220314204036 · Cited by 35
Szabolcs, M. J., Sun, J., Ma, N., Albala, A., Sciacca, R. R., Philips, G. B., Parkinson, J. F., Edwards, N. M., & Cannon, P. (2002) · Circulation · doi:10.1161/01.cir.0000034719.08848.26 · Cited by 34 · cited 1×
“Both BBS-2 and PPA250 were shown to be active in animal models of diseas”
BackgroundSmall molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents
Liu, G. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.9.1383 · Cited by 30 · cited 1×
“Although no small molecules have been shown to bind to LFA1 at the ICAM1 binding site, two classes of allosteric inhibitors have been identifie”
BackgroundArkin, M. R., & Lear, J. D. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5396 · Cited by 29
Self-citationPei, Z., Xin, Z., Liu, G., Li, Y., Reilly, E. B., Lubbers, N. L., Huth, J. R., Link, J. T., von Geldern, T. W., Cox, B. F., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010059w · Cited by 28
Combinatorial chemistry techniques applied to nonpeptide integrin antagonists.
Hoekstra, W., & Poulter, B. L. (1998) · PubMed · Cited by 27
Thibault, E. (2000) · Cited by 27
Rydén, M., & Ibáñez, C. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33085 · Cited by 24
Woska, J. R., Last-Barney, K., Rothlein, R., Kroe‐Barrett, R., Reilly, P. L., Jeanfavre, D. D., Mainolfi, E. A., Kelly, T. A., Caviness, G. O., Fogal, S. E., et al. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00176-5 · Cited by 23
Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion
Sanfilippo, P. J., Jetter, M. C., Cordova, R., Noe, R. A., Chourmouzis, E., Lau, C. Y., & Wang, E. Y. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00007a002 · Cited by 23 · cited 1×
“have reported a series of tri-cyclic compounds that inhibit the LFA1/ICAM1 interaction, but the mechanism has not been characterize”
BackgroundDiscovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists
Link, J. T., Sorensen, B. K., Liu, G., Pei, Z., Reilly, E. B., Leitza, S. T., & Okasinski, G. F. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00105-6 · Cited by 23 · cited 1×
“A third series, represented by compound 19, was initially discovered through HTS and then optimized through medicinal chemistry and a fragment-discovery method called SAR by NMR ( Box 3”
MethodInhibitors of protein-protein interactions
Gadek, T. R., & Ockey, D. A. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.3.393 · Cited by 21
N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure–activity relationship
Burdick, D. J., Paris, K., Weese, K. J., Stanley, M. S., Beresini, M. H., Clark, K., McDowell, R. S., Marsters, J. C., & Gadek, T. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00084-2 · Cited by 19
Characterization of the allosteric inhibition of a protein-protein interaction by mass spectrometry
Davidson, W. C., Hopkins, J. L., Jeanfavre, D. D., Last-Barney, K., Kelly, T. A., & Grygon, C. A. (2002) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(02)00706-7 · Cited by 14 · cited 1×
“The research team at Boehringer Ingelheim has developed mass spectrometry (MS)-based methods to obtain binding-site information for hydantoin antagonists of LFA1 in the absence of NMR or crystallograph”
Method2 Fibrinogen Receptor Antagonists: Design and Clinical Applications
Eldred, C. D., & Judkins, B. D. (1999) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70045-6 · Cited by 13
Wiekowski, M., Prosser, D. M., Taremi, S. S., Tsarbopoulos, A., Jenh, C., Chou, C., Lundell, D. J., Zavodny, P. J., & Narula, S. K. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00625.x · Cited by 13 · cited 1×
“Additionally, some compounds act as protein denaturants or covalent inhibitor”
BackgroundDiscovery of small molecule leads in a biotechnology datastream
Gadek, T. R., & McDowell, R. S. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02735-1 · Cited by 9
Inhibitors of the NOS enzymes: a patent review.
Mete, A., & Connolly, S. (2003) · PubMed · Cited by 8
UNRAVELING THE STRUCTURE OF INTERLEUKIN-2: REPLY
McKay, D., & Brandhuber, B. J. (1992) · Worldwide Protein Data Bank · doi:10.2210/pdb3ink/pdb · Cited by 3
Wang, S. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00074-3 · Cited by 2 · cited 1×
“The authors prepared a number of chimeric B7-1 proteins in which regions of the human (hu) sequence were exchanged for the murine amino acid”
BackgroundZepik (2001) · doi:10.1002/1521-3773(20010105)40:1
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
“Many diseases, such as cancer, can be attributed to defective protein-protein interactions (PPIs); therefore, this type of intermolecular event is a highly attractive target in drug discovery [115].”
BackgroundThe re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Self-citationClick Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.